NCT02400359View on ClinicalTrials.gov

Lorcaserin in Obesity: Identification of CNS Targets Using FMRI

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
ObesityWeight Loss
Interventions
DRUG

Lorcaserin HCl

Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.

DRUG

Placebo

This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER